Follow Us x
ActivePure® Technology is the technology proven to reduce pathogens in the air and on surfaces in real-time.
ActivePure® Technology vs SARS-CoV-2 (The Virus That Causes COVID-19)Testing completed in August 2020 (surface) and December 2020 (airborne) has shown remarkable levels of reduction in the virus that causes COVID-19.
New Air & Surface Pro Unit Testing
Testing done at a 3rd party unaffiliated laboratory with no connection to ActivePure® Technology or its affiliates.
Aerus Hydroxyl Blaster with ActivePure® Technology Unit Testing
Testing was done at MRIGlobal, a 3rd party unaffiliated laboratory with no connection to ActivePure® Technology or its affiliates. The reduction percentages were measured incrementally over natural degradation of SARS-CoV-2. Outside of control group - over 99.9% reduction of the SARS-CoV-2 virus.
ActivePure® Technology Is Proven Against a Wide Range of Pathogens
| ✓ SARS-CoV-2 | ✓ MS2 Bacteriophage - RNA Virus | ✓ Candida auris (fungus) |
| ✓ Staphylococcus Aureus | ✓ Staphylococcus epidermidis (Gram +) | ✓ Botrytis cinerea (fungus) |
| ✓ Aspergillus niger endospores (toxic black mold surrogate) | ✓ PhiX-174 - DNA Virus | ✓ Sclerotinia sclerotiorum (fungus) |
| ✓ H1N1 Influenza (Swine Flu) | ✓ Erwinia Herbicola (Gram -) | ✓ Legionella pneumophila (bacteria) |
| ✓ H5N8 Influenza (Bird Flu) | ✓ Listeria monocytogenes | ✓ Aspergillus versicolor (fungus) |
| ✓ MRSA | ✓ Murine Norovirus | ✓ Clostridium difficile (endospore) |
| ✓ Bacillus globigii (C. difficile & anthrax surrogate) | ✓ E. coli | ✓ Salmonella enterica (bacteria) |
ActivePure® Technology has been proven effective against a broad spectrum of clinically relevant pathogens. Every pathogen has a different level of resistance which is outlined in the hierarchy of pathogens below.
Click here to review our COVID-19 specific test results.
To learn more about the hierarchy of pathogens, review Dr. William Rutala's Overview of Current Disinfection Hierarchy Models.
Performance Backed by Peer-Reviewed Science
A study published in the American Journal of Infection Control (AJIC) shows a proven reduction in MRSA, fungi, and aerobic bacteria air and surface bio-burdens and a greater than 70% reduction in HAIs.
Sustained Reduction in HAIs of 70%+ (CAUTI, CLABSI, C. diff, MRSA)
A decline in total aggregate counts of HAIs (ie, CAUTI, CLABSI, C difficile, MRSA bacteremia, and pneumonia) at both ICUs was observed when compared to a historical count 21 months prior to AP activation for the Louisiana site (71% reduction; 24 HAIs to 7 HAIs) (Fig A) and 12 months prior at the Kentucky site (70% reduction; 10 HAIs to 3 HAIs) (Fig B)
Fig. Aggregate counts of surveilled HAIs comparing matched time periods before and after ActivePure technology activation for Louisiana (A) and Kentucky (B). CAUTI, catheter-associated urinary tract infection; C difficile, Clostridioides difficile; CLABSI, central line-associated bloodstream infection; MRSA, methicillin-resistant Staphylococcus aureus.
Statistically Significant Reductions in Microbial Reservoirs Across the Environment of Care
Environmental Surface Fungal CFU Reduction
Mean fungal CFUs were reduced by 98% at Louisiana site and 99% at the Kentucky site from baseline to postactivation
Environmental Floor Fungal CFU Reduction
Mean fungal CFUs were reduced by 99% at Louisiana site and 98% at the Kentucky site from baseline to postactivation
Environmental Air Bacterial and Fungal CFU Reduction
Mean aerobic bacterial and fungal CFUs were reduced by 72% (27.3 CFUs to 7.7 CFUs) and 89% (10.6 CFUs to 1.18 CFUs), respectively, from baseline to postactivation at Louisiana site. Mean aerobic bacterial CFUs increased by 6% (9.29 CFUs to 9.86 CFUs)1 and mean fungal CFUs were reduced by 27% (1.57 CFUs to 1.14 CFUs) at the Kentucky site.
1 Mean aerobic bacterial air CFUs at the Kentucky site were the only study result to show an increase compared to baseline, which is likely due to the turbulent nature of airflow and ensuing variability of airborne microbe dispersal.
Want to Read the Full Study?
Download the AJIC article here.
